RVTY · Revvity, Inc.
$113.022026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$22
-80.8% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($24 · $10) Analysts Range ($95 · $124) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $2.8B | — | 16.6% | 2.5% | $444MM | −$14MM | $430MM | 8.7% | — | 4.2% | $10.7B | $-1.06 | — |
| 2024.Q4 | $2.8B | 0.0% | 16.6% | 10.5% | $408MM | $272MM | $680MM | 8.6% | — | 3.9% | $10.3B | $-1.06 | — |
| 2025.Q1 | $2.8B | 0.2% | 17.0% | 11.4% | $415MM | $274MM | $689MM | 9.5% | — | 4.0% | $10.2B | $2.64 | — |
| 2025.Q4 | $2.8B | 0.0% | 17.0% | 9.6% | $423MM | $209MM | $632MM | 9.5% | — | 4.1% | $10.3B | $2.64 | — |
| 2026.Q1 | $2.9B | 5.3% | 14.2% | 9.1% | $373MM | $115MM | $488MM | 9.2% | — | 3.7% | $10.2B | $2.15 | 30.8 |
| italics below = DCF projection · 10yr Rev CAGR: 4.1% |
| 2027.Q1 | $2.9B | +-1.2% | 16.1% | 10.2% | $416MM | $0MM | $416MM | 9.2% | $381MM | 4.1% | $10.2B | $2.86 | 39.5 |
| 2028.Q1 | $3.0B | +5.4% | 17.0% | 11.3% | $455MM | −$540MM | −$85MM | 9.1% | −$72MM | 4.4% | $10.7B | $3.23 | 35.0 |
| 2029.Q1 | $3.2B | +6.0% | 17.8% | 12.4% | $499MM | −$623MM | −$124MM | 9.1% | −$95MM | 4.5% | $11.3B | $3.65 | 31.0 |
| 2030.Q1 | $3.4B | +5.4% | 18.6% | 13.5% | $543MM | −$599MM | −$55MM | 9.0% | −$39MM | 4.7% | $11.9B | $4.08 | 27.7 |
| 2031.Q1 | $3.5B | +4.4% | 20.3% | 14.6% | $610MM | −$505MM | $105MM | 9.0% | $68MM | 5.0% | $12.4B | $4.78 | 23.6 |
|
| Term. Yr+ | $4.5B | 4.1% | 20.3% | 20.0% | $731MM | −$348MM | $382MM | 8.6% | $3.6B | 8.6% | — | — | — |
Active scenario IV: $22 (-80.8% vs market)